Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
4
×
life sciences
national blog main
biotech
boston blog main
boston top stories
deals
fda
alexion pharmaceuticals
boston
drugs
national top stories
new york blog main
patisiran
san diego blog main
san diego top stories
achaogen
adams street partners
akcea therapeutics
alnylam pharmaceuticals
amyotrophic lateral sclerosis (als)
antibiotics
anylam pharmaceuticals
autoimmune disorders
beta lactamase inhibitor
biomedical advanced research and development authority (barda)
boehringer ingelheim
cardiomyopathy
complement system
dicerna pharamceuticals
drug resistance
generalized myasthenia gravis
hatteras venture partners
hepatitis b
hepatitis b virus
hereditary transthyretin amyloidosis
immune-mediated necrotizing myopathy
inotersen
investing
lyzz capital
What
disease
4
×
drug
4
×
medicines
4
×
pharma
pharmaceuticals
year
ago
akcea
alnylam
alternative
amyloidosis
approved
attr
autoimmune
available
bacteria
battle
biopharma
business
candidate
caught
causing
company
deal
debilitating
dicerna
exited
expensive
eye
fda
fighting
gene
genetic
hepatitis
infections
infectious
intended
launches
lead
melinta
Language
unset
Current search:
disease
×
drug
×
" clinical trials "
×
medicines
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Qpex Biopharma Launches with $33M to Tackle Drug-Resistant Infections